Format

Send to

Choose Destination
PET Clin. 2015 Jul;10(3):361-74. doi: 10.1016/j.cpet.2015.03.002. Epub 2015 Apr 24.

PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.

Author information

1
Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, Aarhus DK-8200, Denmark. Electronic address: kirsbouc@rm.dk.
2
Molecular Imaging Program, Building 10, Room B3B6B9F, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.

Abstract

Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology. In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers.

KEYWORDS:

Bladder cancer; PET/CT; Renal cancer; Testicular cancer

PMID:
26099672
PMCID:
PMC4479416
DOI:
10.1016/j.cpet.2015.03.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center